Latest Articles about ARQL

Narrower-than-Expected Loss at ArQule - Analyst Blog

Zacks Equity Research — Thu, 09 May 2013 21:24:11 Z

ArQule, Inc. ( ARQL ) recently reported a loss of 9 cents per share in the first quarter of 2013, narrower than the Zacks Consensus Estimate of a loss of 11 cents per share. The company had

Data on ArQule's ARQ 092 - Analyst Blog

Zacks Equity Research — Thu, 11 Apr 2013 01:10:01 Z

Researchers recently presented data on ArQule's ( ARQL ) ARQ 092 at the American Association for Cancer Research (AACR) Annual Meeting held in Washington, D.C. The data revealed that the

ArQule Regains ARQ 092 Rights - Analyst Blog

Zacks Equity Research — Wed, 03 Apr 2013 02:20:01 Z

ArQule, Inc. ( ARQL ) recently announced that the company has regained global rights for the development and commercialization of compounds, which are covered under its AKT collaboration

ArQule's Loss Narrower than Expected - Analyst Blog

Zacks Equity Research — Tue, 19 Mar 2013 23:48:31 Z

ArQule, Inc . ( ARQL ) recently reported a loss of 9 cents per share in the fourth quarter of 2012, narrower than the Zacks Consensus Estimate of 13 cents per share. The company had

3 Biopharma Catalyst Trades To Consider For Today

Trefis Team — Wed, 06 Feb 2013 21:23:37 Z

Submitted by Scott Matusow as part of our contributors program . While catalyst trading small-cap biopharmas can be risky, if done with the correct discipline and closely following the

Synergy Starts SP-333 Phase I Study - Analyst Blog

Zacks Equity Research — Wed, 30 Jan 2013 02:50:01 Z

Synergy Pharmaceuticals Inc. ( SGYP ) recently initiated a phase Ib study on its inflammatory bowel disease (IBD) candidate, SP-333. SP-333, a guanylate cyclase C (GC-C) agonist, is

Setback for ArQule, Shares Fall - Analyst Blog

Zacks Equity Research — Mon, 14 Jan 2013 23:20:01 Z

ArQule Inc. ( ARQL ) and partner Daiichi Sankyo recently announced disappointing phase II results on oncology candidate, tivantinib (ARQ 197). The study evaluated ArQule's lead pipeline

Pre-Market Most Active for Jan 11, 2013 : MT, BAC, WFC, NOK, DNDN, BBY, SAP, FB, RIMM, SIRI, AAPL, ARQL

NASDAQ.com News — Fri, 11 Jan 2013 18:39:54 Z

The NASDAQ 100 Pre-Market Indicator is down -2.35 to 2,741.83. The total Pre-Market volume is currently 2,879,057 shares traded. The following are the most active stocks for the pre-market

Zacks #1 Rank Additions for Wednesday - Tale of the Tape

Zacks Equity Research — Wed, 03 Oct 2012 16:49:47 Z

Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: AllianceBernstein Holding LP ( AB ) The Allstate Corp. ( ALL ) American Science &

Zacks #1 Rank Additions for Tuesday - Tale of the Tape

Zacks Equity Research — Tue, 07 Aug 2012 17:14:01 Z

Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: The Advisory Board Co. ( ABCO ) AerCap Holdings N.V. ( AER ) American Water Works Co., Inc. ( AWK

Pre-Market Earnings Report for August 2, 2012 : APA, AEE, ANSS, ARIA, APO, ALE, AB, ABMD, AYR, AVD, ARQL, AGEN

NASDAQ.com News — Thu, 02 Aug 2012 00:08:40 Z

The following companies are expected to report earnings prior to market open on 08/02/2012. Visit our Earnings Calendar for a full list of expected earnings releases. Apache Corporation (

Zacks #1 Rank Additions for Tuesday - Tale of the Tape

Zacks Equity Research — Tue, 01 May 2012 17:14:01 Z

Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: 3D Systems Corp. ( DDD ) AGCO Corp. ( AGCO )

Zacks #1 Rank Additions for Monday - Tale of the Tape

Zacks Equity Research — Mon, 02 Apr 2012 17:14:01 Z

Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: Allot Communications Ltd. ( ALLT ) ArQule, Inc. ( ARQL )

Company News for January 18, 2012 - Corporate Summary

Zacks Equity Research — Wed, 18 Jan 2012 19:00:01 Z

• Bio technology company ArQule Inc.'s (NASDAQ: ARQL ) share prices gained 11.91% to close at $6.67 after the company's experimental treatment for liver cancer

Monday Losers: Delcath, CVS Caremark and Coldwater Creek

David Sterman — Mon, 07 Jun 2010 19:04:09 Z

Among the biggest losers in Monday's early trading are Delcath ( DCTH ) , CVS Caremark ( CVS ) and Coldwater Creek (Nasdaq: CWTR) . Top